A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Status:
Completed
Trial end date:
2019-01-22
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of ramucirumab in combination with
other targeted agents in participants with advanced cancers.